PSMA PET/CT in Renal Cell Carcinoma: An Overview of Current Literature

Stijn Muselaers; Selcuk Erdem; Riccardo Bertolo; Alexandre Ingels; Önder Kara; Nicola Pavan; Eduard Roussel; Angela Pecoraro; Michele Marchioni; Umberto Carbonara; Laura Marandino; Daniele Amparore; Riccardo Campi; On Behalf Of The European Association Of Urology Eau Young Academic Urologists Yau Renal Cancer Working Group

doi:10.3390/jcm11071829

PSMA PET/CT in Renal Cell Carcinoma: An Overview of Current Literature

J Clin Med. 2022 Mar 25;11(7):1829. doi: 10.3390/jcm11071829.

Authors

Affiliations

¹ Department of Urology, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands.
² Division of Urologic Oncology, Department of Urology, Faculty of Medicine, Istanbul University, Istanbul 34452, Turkey.
³ Department of Urology, San Carlo Di Nancy Hospital, 00165 Rome, Italy.
⁴ Department of Urology, University Hospital Henri Mondor, APHP, 94000 Créteil, France.
⁵ Department of Urology, School of Medicine, Kocaeli University, İzmit 41001, Turkey.
⁶ Urology Clinic, Department of Medical, Surgical and Health Science, University of Trieste, 34127 Trieste, Italy.
⁷ Department of Urology, University Hospitals Leuven, 3000 Leuven, Belgium.
⁸ Department of Urology, San Luigi Gonzaga Hospital, University of Turin, Orbassano, 10124 Turin, Italy.
⁹ Department of Medical, Oral and Biotechnological Sciences, G. d'Annunzio University of Chieti, 66100 Chieti, Italy.
¹⁰ Department of Emergency and Organ Transplantation-Urology, Andrology and Kidney Transplantation, University of Bari, 70121 Bari, Italy.
¹¹ Department of Medical Oncology, IRCCS Ospedale San Raffaele, 20132 Milan, Italy.
¹² Unit of Urological Robotic Surgery and Renal Transplantation, Careggi Hospital, University of Florence, 50121 Florence, Italy.

Abstract

Although the vast majority of prostate-specific membrane antigen (PSMA) positron emission tomography (PET) imaging occurs in the field of prostate cancer, PSMA is also highly expressed on the cell surface of the microvasculature of several other solid tumors, including renal cell carcinoma (RCC). This makes it a potentially interesting imaging target for the staging and monitoring of RCC. The objective of this review is to provide an overview of the current evidence regarding the use of PSMA PET/Computed Tomography in RCC patients.

Keywords: PSMA PET/CT; imaging; kidney cancer; renal cell carcinoma.

Publication types

Review